Refine by
Hematologic Malignancies Equipment & Supplies In Iran
12 equipment items found
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR039. INDICATION: r/r B-NHL. PLATFORM: CAR-T. PRECLINICAL: CD20/CD19. IIT²: - PHASE 1/1B: - PHASE 2: - PARTNERS: Johnson & ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR066. INDICATION: r/r B-NHL. PLATFORM: CAR-T. PRECLINICAL: CD20. IIT²: - PHASE 1/1B: - PHASE 2: - PARTNERS: Johnson & ...
Manufactured by:Precision For Medicine, Inc. based inFrederick, MARYLAND (USA)
Advancing your research into hematological malignancies, immunology, and other related areas requires access to high quality human bone marrow mononuclear cells. Precision for Medicine has an extensive inventory of normal, healthy donors with longitudinal data and ability to recall for additional biospecimen ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and c-MYC, an important oncogene across multiple tumor ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper ...
Manufactured by:Antengene Corporation Limited based inChangning District, CHINA
Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. 1,2 MM primarily occurs in the elderly population. In the Chinese population, MM is the second most common hematologic malignancy, 3,4 with a median age of onset of 59 years1 and an incidence rate of 1.46 per 100,0004 that is lower than that of ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
Many hematologic malignancies carry characteristic chromosomal translocations believed to play an important role in the pathogenesis of these tumors. Chromosomal translocations found in leukemias and lymphomas either fuse enhancer/promoter regions of one gene to another, causing aberrant expression, or by fusing a part of one gene to that of another, resulting in ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Mechanism: BCL2/xL; Area under investigation: haematological malignancies; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China; Additional information: Partnered product. Molecule size: Small molecule; Status ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC restricted and not ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The reason for this may be that previous vaccine models used inadequate ...